Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate

Abstract

Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR109A) agonists. Compound 1e (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.

References

Page 1

	Year	Citations
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Sorin Tunaru, Jukka Kero, Annette Schaub, Nature Medicine Molecular PhysiologyAnti-lipolytic EffectBiochemistryMedicineNicotine	2003	787
(d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G Andrew K.P. Taggart, Jukka Kero, Xiaodong Gan, Journal of Biological Chemistry	2005	636
Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid Alan Wise, Steven M. Foord, Neil J. Fraser, Journal of Biological Chemistry	2003	536
Pd-Catalyzed Intermolecular Amidation of Aryl Halides: The Discovery that Xantphos Can Be Trans-Chelating in a Palladium Complex Jingjun Yin, Stephen L. Buchwald Journal of the American Chemical Society	2002	466
GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing Zoltán Benyó, Andreas Gille, Jukka Kero, Journal of Clinical Investigation	2005	336
Antagonism of the prostaglandin D <sub>2</sub> receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Kang Cheng, Tsuei-Ju Wu, Kenneth K. Wu, Proceedings of the National Academy of Sciences InflammationMolecular PharmacologySignal TransductionMolecular PhysiologyMedicine	2006	268
Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. E Nikkilä, P Viikinkoski, M. Valle, BMJ Lipid DisorderCoronary AtherosclerosisCardiovascular DiseasePharmacologyPatients Total Cholesterol	1984	136
One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Wendy J. Mack, Robert H. Selzer, Howard N. Hodis, Stroke	1993	126
Biotransformation of phenol to hydroquinone and catechol by rat liver microsomes. Tadashi Sawahata, Robert A. Neal Molecular Pharmacology	1983	103
Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor Hong C. Shen, Fa‐Xiang Ding, Silvi Luell, Journal of Medicinal Chemistry Drug TargetImmunologyPharmacotherapyMedicinal ChemistryReceptor Gpr109a	2007	36

Page 1